Drug
Orgalutran®
Orgalutran® is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
3
60%
Ph phase_2
1
20%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
3(75.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(3)
Other(1)
Detailed Status
Completed3
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 43 (75.0%)
Trials by Status
recruiting120%
unknown120%
completed360%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_4
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
NCT06175832
completedphase_2
Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)
NCT00702806
completed
Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®
NCT01304511
unknownphase_4
Desogestrel Versus GnRH Antagonist in IVF/ICSI
NCT04728659
completedphase_4
Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
NCT02796105
Clinical Trials (5)
Showing 5 of 5 trials
NCT06175832Phase 4
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
NCT00702806Phase 2
Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)
NCT01304511
Post-Marketing Surveillance of the Safety and Efficacy of Orgalutran (Ganirelix)®
NCT04728659Phase 4
Desogestrel Versus GnRH Antagonist in IVF/ICSI
NCT02796105Phase 4
Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5